Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3495901 | 0.83 | MCL1 (0.49) | LMNAMAPK1GPR3HDAC1HDAC8 | |
| SCHEMBL3319350 | 0.81 | LMNA (0.44) | LMNAMAPK1GPR3CNR2CNR1 | |
| SCHEMBL11379316 | 0.79 | LMNA (0.49) | LMNAMAPK1GPR3CNR2CNR1 | |
| SCHEMBL9556945 | 0.79 | LMNA (0.49) | LMNAMAPK1GPR3CNR2CNR1 | |
| SCHEMBL2503631 | 0.74 | PTGS2 (0.56) | LMNAMAPK1GPR3ATMHDAC1 | |
| SCHEMBL28435284 | 0.73 | TSHR (0.51) | LMNAMAPK1CNR2L3MBTL1TDP1 | |
| Dibenzothiophene SCHEMBL11884108 | 0.71 | GPR3 (0.67) | LMNAMAPK1GPR3ATMLIMK1 | |
| SCHEMBL31146421 | 0.70 | THRB (0.52) | LMNAL3MBTL1MCL1KDM4EMEN1 | |
| SCHEMBL181822 | 0.70 | THRB (0.52) | LMNAL3MBTL1MCL1KDM4EMEN1 | |
| SCHEMBL28479943 | 0.70 | MAPT (0.52) | LMNAMAPK1GPR3L3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. (US) | 2022-12-15 | — | — | US | disclosed |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | Janssen Biopharma, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | LMNA 2538/4885MAPK1 4019/4885GPR3 3907/4885 |
| US-20220396581-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | LMNA 2835/4885MAPK1 4174/4885GPR3 4319/4885 |
| US-11014935-B2 | Compounds for the treatment of paramyxovirus viral infections | MAVS, SARS1, ZC3HAV1 | LMNA 2835/4885MAPK1 4174/4885GPR3 4319/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | LMNA 2835/4885MAPK1 4174/4885GPR3 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.